Pantoprazol Krka (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Krka, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children.

GNH USA supplies Pantoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces the risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare neuroendocrine tumor. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory therapy.

Pantoprazol Krka is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional and self‑limiting. - Abdominal pain: mild discomfort. - Flatulence: increased gas. - Constipation: occasional.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: signs of hepatic dysfunction. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation.

When prescribing Pantoprazol Krka, clinicians should consider several safety aspects: - Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Long‑term therapy: assess need for continued use to minimise fracture risk. - Drug interactions: review concomitant medications that may affect acid levels or metabolism. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at ambient temperature: keep below 25 °C, protect from moisture and retain in original packaging.

Pantoprazol Krka can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (e.g., ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - HIV protease inhibitors (e.g., atazanavir, nelfinavir): markedly decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring closer coagulation monitoring. - Methotrexate (high‑dose): reduced renal clearance may raise toxicity risk. - Digoxin: slight increase in serum levels, monitor for toxicity. - Clopidogrel: possible reduction in antiplatelet effect, consider alternative therapy.